Calidi Biotherapeutics to Raise $10M in Direct Offering
Ticker: CLDWW · Form: 8-K · Filed: Aug 29, 2025 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: capital-raise, direct-offering, financing
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics is selling $10M in stock and warrants, closing soon.
AI Summary
Calidi Biotherapeutics, Inc. reported on August 29, 2025, that it has entered into a securities purchase agreement. The company plans to issue and sell approximately $10.0 million of its common stock and warrants in a registered direct offering. This offering is expected to close on or about August 30, 2025, subject to customary closing conditions.
Why It Matters
This capital raise could provide Calidi Biotherapeutics with crucial funding for its operations and development pipeline, potentially impacting its ability to advance its therapeutic programs.
Risk Assessment
Risk Level: medium — The company is raising capital through a direct offering, which can dilute existing shareholders and may indicate a need for funds to support ongoing operations or development.
Key Numbers
- $10.0M — Capital Raise (Amount to be raised in a registered direct offering of common stock and warrants.)
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- $10.0 million (dollar_amount) — Amount to be raised in securities purchase agreement
- August 29, 2025 (date) — Date of earliest event reported
- August 30, 2025 (date) — Expected closing date of the offering
- CLDI (company) — Trading Symbol
FAQ
What is the purpose of the registered direct offering?
The filing does not explicitly state the purpose of the offering, but it is a common method for biotechnology companies to raise capital for research, development, and general corporate purposes.
What are the terms of the warrants being offered?
The filing mentions that warrants are being sold along with common stock, but it does not provide specific details regarding the terms of these warrants, such as exercise price or expiration date.
Who is the underwriter or placement agent for this offering?
The filing does not name any specific underwriter or placement agent involved in the registered direct offering.
What is the expected net proceeds from the offering?
The filing states the gross amount to be raised is approximately $10.0 million, but does not provide an estimate of the net proceeds after deducting offering expenses.
Are there any specific conditions to closing the offering mentioned?
Yes, the filing states that the closing is subject to customary closing conditions.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-08-29 17:20:03
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 248KB
- ex99-1_002.jpg (GRAPHIC) — 547KB
- ex99-1_003.jpg (GRAPHIC) — 234KB
- ex99-1_004.jpg (GRAPHIC) — 289KB
- ex99-1_005.jpg (GRAPHIC) — 451KB
- ex99-1_006.jpg (GRAPHIC) — 381KB
- ex99-1_007.jpg (GRAPHIC) — 340KB
- ex99-1_008.jpg (GRAPHIC) — 275KB
- ex99-1_009.jpg (GRAPHIC) — 265KB
- ex99-1_010.jpg (GRAPHIC) — 313KB
- ex99-1_011.jpg (GRAPHIC) — 352KB
- ex99-1_012.jpg (GRAPHIC) — 249KB
- ex99-1_013.jpg (GRAPHIC) — 363KB
- ex99-1_014.jpg (GRAPHIC) — 349KB
- ex99-1_015.jpg (GRAPHIC) — 202KB
- ex99-1_016.jpg (GRAPHIC) — 350KB
- 0001641172-25-026066.txt ( ) — 7391KB
- cldi-20250829.xsd (EX-101.SCH) — 3KB
- cldi-20250829_lab.xml (EX-101.LAB) — 33KB
- cldi-20250829_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: August 29, 2025 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer